Blueberries Medical Corp (TSE:BBM)
:BBM
Want to see TSE:BBM full AI Analyst Report?
Top Page
Blueberries Medical
(BBM)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.01
▼(-30.00% Downside)
Action:ReiteratedDate:05/01/26
The score is driven primarily by weak financial performance—persistent losses, ongoing cash burn, and a 2025 revenue decline—partially offset by low current debt. Technical indicators are mixed-to-soft, and valuation metrics are constrained by negative earnings and the absence of a dividend.
Positive Factors
Low leverage / manageable debt
Very low reported debt in 2024–2025 reduces refinancing and interest burden risk, giving management more optionality to prioritize R&D, regulatory work, or commercialization. Durable low leverage supports flexibility during a multi-quarter recovery without immediate solvency pressure.
Negative Factors
Persistent negative operating and free cash flow
Consistent negative operating and free cash flow means the business consumes cash rather than funds itself, creating ongoing reliance on external financing. That structural cash burn limits reinvestment, increases dilution/refinancing risk, and constrains runway absent a sustained shift to positive cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / manageable debt
Very low reported debt in 2024–2025 reduces refinancing and interest burden risk, giving management more optionality to prioritize R&D, regulatory work, or commercialization. Durable low leverage supports flexibility during a multi-quarter recovery without immediate solvency pressure.
Read all positive factors
Blueberries Medical (BBM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$7.43M
Dividend YieldN/A
Average Volume (3M)5.76K
Price to Earnings (P/E)―
Beta (1Y)-3.35
Revenue Growth-33.76%
EPS Growth-27.59%
CountryCA
Employees51
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding495,090,100
10 Day Avg. Volume100
30 Day Avg. Volume5,759
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)14.73
Price to Sales (P/S)15.15
P/FCF Ratio-3.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Blueberries Medical Business Overview & Revenue Model
Company Description
Blueberries Medical Corp. engages in the growth, cultivation, development, production, and supply of medicinal cannabis and related products in Colombia. It offers medicinal-grade cannabis oil extracts and related products. The company is headquar...
Blueberries Medical Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 312.29K | 471.41K | 288.27K | 235.45K | 138.75K |
| Gross Profit | 49.50K | 164.52K | 84.22K | -17.72K | -245.45K |
| EBITDA | -1.28M | -1.04M | -1.22M | -811.47K | -4.05M |
| Net Income | -1.67M | -1.15M | -1.64M | -1.47M | -5.15M |
Balance Sheet | |||||
| Total Assets | 679.62K | 1.38M | 2.42M | 3.35M | 3.59M |
| Cash, Cash Equivalents and Short-Term Investments | 26.39K | 66.08K | 818.16K | 1.41M | 1.34M |
| Total Debt | 7.18K | 11.44K | 12.80K | 1.34M | 1.44M |
| Total Liabilities | 358.45K | 545.61K | 470.72K | 1.89M | 2.16M |
| Stockholders Equity | 321.17K | 834.81K | 1.95M | 1.47M | 1.43M |
Cash Flow | |||||
| Free Cash Flow | -1.24M | -796.85K | -1.35M | -1.47M | -1.73M |
| Operating Cash Flow | -1.24M | -796.85K | -1.33M | -1.47M | -1.68M |
| Investing Cash Flow | 0.00 | 9.00K | 382.92K | 101.94K | -48.77K |
| Financing Cash Flow | 1.18M | -1.95K | 539.10K | 1.35M | 2.77M |
Blueberries Medical Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
<0.01
Positive
35.29
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 35.29 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BBM.
Blueberries Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$24.66M | -1.56 | -461.32% | ― | 83.87% | -72.88% | |
46 Neutral | C$5.49M | -6.37 | 50.26% | ― | -0.55% | -222.37% | |
42 Neutral | C$7.43M | -2.84 | -167.41% | ― | -33.76% | -27.59% | |
40 Underperform | C$1.95M | -1.54 | -271.33% | ― | 15.95% | -1.81% |
* Healthcare Sector Average
TSE:BBM
Blueberries Medical
0.02
<0.01
50.00%
TSE:AYUR
Ayurcann Holdings Corp.
0.01
-0.02
-60.00%
TSE:MVMD
Mountain Valley MD
0.07
0.05
180.00%
TSE:BAMM
Body & Mind
0.03
0.00
0.00%
TSE:CDVA
CordovaCann
0.05
-0.10
-66.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.